Crotoxin Reduces Colitis Via Formyl Peptide Receptors

Snake venom might seem an unlikely source of new gut treatments, but research shows its components can powerfully modulate the immune system. A new study in Frontiers in Immunology demonstrates that crotoxin (CTX), the main toxin in the venom of a South American rattlesnake, can significantly reduce intestinal inflammation in a mouse model of colitis and modulate human gut epithelial cell responses. The protective effect appears to be channeled through specific formyl peptide receptors (FPRs) on cells.

How Crotoxin Calmed Human Gut Cells in the Lab

Led by Bianca de C. L. F. Távora, Sarah Natalie Cirilo Gimenes, and Isabella Mitie de Camargo, the team first wanted to understand how crotoxin interacts directly with the intestinal barrier. They used Caco-2 cells, a standard model for human gut epithelium.

The cells were stimulated with the pro-inflammatory cytokine interferon-gamma (IFN-γ), which triggers a breakdown in barrier integrity and promotes inflammation—key events in conditions like IBD. When CTX was added alongside IFN-γ, it produced a clear protective effect. The toxin helped maintain the expression of ZO-1, a critical protein that stitches gut epithelial cells tightly together. It also reduced levels of ICAM-1, a surface molecule that attracts immune cells, and lowered the secretion of IL-8, a potent inflammatory signal.

This combination of effects meant that CTX-treated epithelial cells were less disruptive to the immune system. In a functional test, media from IFN-γ-stimulated Caco-2 cells attracted neutrophils and monocytes. Media from cells treated with both IFN-γ and CTX attracted significantly fewer of these inflammatory cells.

Reducing Acute Colitis and Dysbiosis in Mice

The researchers then tested CTX in a live animal model of acute intestinal inflammation. Mice received an intrarectal instillation of TNBS, a chemical that induces a robust, colitis-like condition characterized by weight loss, tissue necrosis, and heavy immune infiltration.

Administration of CTX significantly improved outcomes. Treated mice lost less weight, had better clinical scores, and showed smaller areas of tissue damage. Analysis of the colon tissue revealed that CTX reduced the recruitment of neutrophils, monocytes, and macrophages into the lamina propria—the layer of tissue beneath the epithelium.

Notably, CTX also impacted the gut ecosystem. The TNBS challenge caused a significant shift in the gut microbiota composition, a state known as dysbiosis. CTX treatment partially reversed this shift, suggesting its benefits extend beyond just calming the immune system to also support a healthier microbial environment. This interaction between host immune response and microbial community balance is central to many gut disorders.

The Critical Role of Formyl Peptide Receptors

A crucial part of the experiment was identifying how CTX works. The researchers suspected formyl peptide receptors (FPRs) might be involved. These receptors, found on epithelial and immune cells, detect bacterial molecules and host-derived signals to regulate inflammation. Some FPRs help resolve inflammation.

To test this, they used a compound called Boc 2, which blocks FPR activity. When mice were given Boc 2 alongside CTX, all the protective effects vanished. The mice experienced severe colitis equivalent to the untreated group. This result strongly indicates that CTX exerts its anti-inflammatory action by activating specific FPR pathways. This makes FPRs a highly interesting target for future drug development in IBD, as targeting them could directly influence the cross-talk between immune signaling and tissue health.

Practical Implications and Future Therapeutic Potential

The study does not suggest using actual snake venom as a treatment. Instead, it identifies a precise molecular mechanism—FPR activation—that can powerfully regulate gut inflammation and barrier function. This opens a new avenue for designing synthetic drugs that mimic CTX’s action on FPRs without the toxicity of the full venom.

Such a therapy would aim to interrupt the early, damaging events in an IBD flare or other severe intestinal inflammation. By preserving the epithelial barrier and reducing the signals that call in destructive immune cells, an FPR-targeted drug could prevent the cycle of inflammation from escalating. This approach aligns with a growing focus in gastroenterology on maintaining barrier integrity as a fundamental treatment goal for conditions like IBS and SIBO, where low-grade inflammation and barrier dysfunction are often present.

Furthermore, the observed effect on the microbiota suggests these pathways are deeply interconnected. A therapy that calms the host immune response can create a more stable environment for beneficial microbes to thrive, which in turn supports overall gut health and resilience. This systemic view of gut health, where immune function and microbial ecology are linked, is also a key consideration for long-term health and aging.

Conclusion

This research provides clear evidence that crotoxin, via formyl peptide receptors, can modulate key drivers of intestinal inflammation: epithelial barrier breakdown, immune cell recruitment, and microbial dysbiosis. While derived from an unusual source, the finding emphasizes the importance of FPRs as a regulatory switch in gut immunity. Developing safe, targeted FPR agonists could lead to a novel class of treatments designed to restore tolerance and break the cycle of inflammation in IBD and related conditions.

Source: Távora BCLF, Gimenes SNC, de Camargo IM. Crotoxin attenuates acute colitis by regulating epithelial and immune responses and modulating the gut microbiota via formyl peptide receptors. Front Immunol. 2026;17:1886884.